Jacob J. Orme
YOU?
Author Swipe
Reversing enhancer RNA–mediated IKBKE gene repression enables synthetic anticancer immunity in prostate cancer models Open
Immunotherapy has been effective in many cancer types but has failed in multiple clinical trials in prostate cancers, with the underlying mechanisms remaining largely unclear. Here, we demonstrate that androgen receptor pathway inhibitor (…
Circulating immune factors predict outcomes in CRPC 4250 Open
Description Background Castration-resistant prostate cancers (CRPC) do not respond to immunotherapy.1,2 Prostate cancer-derived immune factors (IF) like sPD-L1 drive immunosuppression and resistance.3 Circulating tumor-reactive T cells (TT…
View article: Real-World Outcomes of Enfortumab Vedotin and Pembrolizumab in Advanced Urothelial Carcinoma: A Multicenter Retrospective Analysis
Real-World Outcomes of Enfortumab Vedotin and Pembrolizumab in Advanced Urothelial Carcinoma: A Multicenter Retrospective Analysis Open
In this real-world cohort, enfortumab vedotin-pembrolizumab combination demonstrated meaningful clinical activity and manageable toxicity in both first-line and subsequent-line settings, consistent with results from the EV-302 trial.
View article: P17.34.B BELZUTIFAN IN CLINICAL PRACTICE: OUTCOMES AND SAFETY IN A REAL-WORLD COHORT OF PATIENTS WITH VHL-ASSOCIATED NEOPLASMS
P17.34.B BELZUTIFAN IN CLINICAL PRACTICE: OUTCOMES AND SAFETY IN A REAL-WORLD COHORT OF PATIENTS WITH VHL-ASSOCIATED NEOPLASMS Open
BACKGROUND Von Hippel-Lindau (VHL) disease is a hereditary cancer syndrome characterized by development of multiple neoplasms, including central nervous system (CNS) hemangioblastomas, renal cell carcinoma (RCC), pancreatic neuroendocrine …
View article: Evolution of Potentially Actionable Genomic Alterations in Advanced Prostate Cancer: A Real-World Analysis of Serial Circulating Tumor DNA Testing
Evolution of Potentially Actionable Genomic Alterations in Advanced Prostate Cancer: A Real-World Analysis of Serial Circulating Tumor DNA Testing Open
Background: Longitudinal genomic profiling through serial circulating tumor DNA (ctDNA) testing offers a noninvasive method to monitor clonal evolution in advanced prostate cancer. This study evaluated the frequency and nature of newly eme…
View article: Off-pore Nucleoporin sPOM121 Transcriptionally Propels β-Catenin–driven Tumor Progression and Immune Escape in Prostate Cancer
Off-pore Nucleoporin sPOM121 Transcriptionally Propels β-Catenin–driven Tumor Progression and Immune Escape in Prostate Cancer Open
The roles of nucleoplasm-residing nucleoporins (NUP) in solid tumors, including prostate cancer, remain unknown. In this study, we reveal the clinical significance and mechanistic role of the off-pore NUP, soluble POM121 (sPOM121), as a cr…
View article: Deferral of systemic therapy in patients with oligorecurrent prostate cancer treated with metastasis-directed radiotherapy
Deferral of systemic therapy in patients with oligorecurrent prostate cancer treated with metastasis-directed radiotherapy Open
Distant metastasis marks a critical transition in prostate cancer, separating potentially curable from canonically incurable disease. Oligometastatic disease, defined as limited metastases (e.g., less than 3, 5, or 10), can encompass diffe…
Evaluating therapeutic plasma exchange and protease inhibitors as mechanisms to reduce soluble mesothelin Open
Cell surface mesothelin (MSLN) can be solubilized and released into the systemic circulation. The resulting soluble MSLN (sMSLN) may interfere with therapies targeting surface MSLN. We investigated the effects of sMSLN on anetumab, an anti…
View article: Systemic treatment options for metastatic castration resistant prostate cancer: A living systematic review
Systemic treatment options for metastatic castration resistant prostate cancer: A living systematic review Open
Background Optimal treatment selection for metastatic castration resistant prostate cancer (mCRPC) remains challenging due to evolving standards of care in castration sensitive setting. Purpose To synthesize and appraise evidence on system…
View article: Supplementary Figure S7 from PSMA<sup>+</sup> Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts
Supplementary Figure S7 from PSMA<sup>+</sup> Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts Open
Progression-free survival stratified by baseline PSA DT levels
View article: Supplementary Figure S5 from PSMA<sup>+</sup> Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts
Supplementary Figure S5 from PSMA<sup>+</sup> Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts Open
Progression-free survival stratified by baseline PSA levels in pooled cohorts
View article: Supplementary Figure S8 from PSMA<sup>+</sup> Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts
Supplementary Figure S8 from PSMA<sup>+</sup> Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts Open
Progression-free survival stratified by PSMA+EV levels
View article: Supplementary Figure S2 from PSMA<sup>+</sup> Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts
Supplementary Figure S2 from PSMA<sup>+</sup> Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts Open
Oncological outcomes of the study cohorts
View article: Supplementary Figure S4 from PSMA<sup>+</sup> Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts
Supplementary Figure S4 from PSMA<sup>+</sup> Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts Open
Progression-free survival stratified by number of lesions treated
View article: Supplementary Figure S1 from PSMA<sup>+</sup> Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts
Supplementary Figure S1 from PSMA<sup>+</sup> Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts Open
Diagram of the study cohorts
View article: Supplementary Figure S6 from PSMA<sup>+</sup> Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts
Supplementary Figure S6 from PSMA<sup>+</sup> Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts Open
Progression-free survival stratified by baseline PSA levels in separate study cohorts
View article: Supplementary Figure S11 from PSMA<sup>+</sup> Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts
Supplementary Figure S11 from PSMA<sup>+</sup> Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts Open
Association of baseline PSA levels with biochemical and radiographic PFS in ORIOLE SABR and observation arms
View article: Data from PSMA<sup>+</sup> Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts
Data from PSMA<sup>+</sup> Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts Open
Purpose:Two randomized clinical trials (STOMP and ORIOLE) demonstrated that stereotactic ablative radiotherapy (SABR) can prolong androgen-deprivation therapy–free survival or progression-free survival (PFS) in patients with metachronous o…
View article: Supplementary Figure S10 from PSMA<sup>+</sup> Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts
Supplementary Figure S10 from PSMA<sup>+</sup> Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts Open
Association of baseline PSMA+EV levels with radiographical PFS in ORIOLE SABR and observation arms
View article: Supplementary Table S1 from PSMA<sup>+</sup> Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts
Supplementary Table S1 from PSMA<sup>+</sup> Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts Open
Multivariate analysis of the risk of progression for baseline PSMA+EV, PSA and PSA DT in the pooled STOMP-like and ORIOLE cohort
View article: Supplementary Figure S9 from PSMA<sup>+</sup> Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts
Supplementary Figure S9 from PSMA<sup>+</sup> Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts Open
Progression-free survival stratified by baseline PSA and PSMA+EV
View article: Supplementary Figure S3 from PSMA<sup>+</sup> Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts
Supplementary Figure S3 from PSMA<sup>+</sup> Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts Open
Comparative analysis of baseline PSA and PSMA+EV between study cohorts
Plasma exchange and radiation resensitize immunotherapy-refractory melanoma: a phase I trial Open
Immune checkpoint inhibitors (ICI) are effective for advanced melanoma. However, most develop ICI resistance. Tumor-derived soluble PD-L1 (sPD-L1) and other immunosuppressive factors drive resistance. We hypothesized that therapeutic plasm…
View article: Data from Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes
Data from Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes Open
Purpose:Around 10% to 15% of prostate cancers harbor recurrent aberrations in the Forkhead Box A1 gene, FOXA1, whereby the alteration type and the effect on the forkhead (FKH) domain affect protein function. We developed a FOXA1 classifica…
View article: Figure 4 from Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes
Figure 4 from Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes Open
Treatment-associated outcomes by FOXA1 alteration class. The survival analysis is conducted on patients who received (A) first-line ADT, including goserelin, leuprolide, triptorelin, degarelix, and relugolix. B, Second-generation ARSI, inc…
View article: Supplementary Figure 1-10 from Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes
Supplementary Figure 1-10 from Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes Open
Supplementary Figures 1-10
View article: Figure 5 from Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes
Figure 5 from Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes Open
Molecular associations by FOXA1 alteration class. Percentages of (A) TMPRSS2–ERG fusions, (B) TP53 mutations, (C) MSI-high status, and (D) TMB-high status based on FOXA1 alteration classes. All q values are relative to WT cases. Percentage…
View article: Figure 1 from Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes
Figure 1 from Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes Open
FOXA1 alterations in prostate cancer. A, Bar graphs showing percentages of amplifications and mutations found in the top 20 cancers with FOXA1 alterations from the Caris Life Sciences POA database. CUP, carcinoma of unknown primary; CRC, c…